Mymetics Corporation (MYMX)
OTCMKTS
· Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
At close: Dec 12, 2025
Mymetics Company Description
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland.
The company’s product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria.
Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of health.
The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001.
Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
Mymetics Corporation
| Country | United States |
| Founded | 1990 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
Contact Details
Address: ROUTE DE LA CORNICHE 4 Epalinges, Delaware 1066 Switzerland | |
| Phone | 41 21 566 5772 |
| Website | mymetics.com |
Stock Details
| Ticker Symbol | MYMX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | US62856A1025 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald Kempers | Chief Executive Officer, Chief Operating Officer, President and Chief Financial Officer |
| Mario Amacker Ph.D. | Head of Quality and Manufacturing |